Serum valproate levels with oral contraceptive use.

Epilepsia

Harvard Neuroendocrine Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Published: June 2005

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1528-1167.2005.00605.xDOI Listing

Publication Analysis

Top Keywords

serum valproate
4
valproate levels
4
levels oral
4
oral contraceptive
4
serum
1
levels
1
oral
1
contraceptive
1

Similar Publications

Objectives: This experiment was carried out to investigate the protective effects of curcumin (CUR) on testicular damage induced by the valproic acid (VPA) administration.

Materials And Methods: Male Wistar-Albino rats (n=28, 250-300 g) were randomly divided into four groups: Control (1 ml saline, oral), VPA (500 mg/kg, IP), CUR (200 mg/kg, oral), or VPA+CUR (500 mg/kg, VPA, IP plus 200 mg/kg CUR, oral). The treatments were applied for 14 days.

View Article and Find Full Text PDF

Background: Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by mutations in the TSC1 and TSC2 genes, leading to the dysregulation of the mammalian target of rapamycin (mTOR) pathway. This dysregulation results in the development of benign tumors across multiple organ systems and poses significant neurodevelopmental challenges. The clinical manifestations of TSC vary widely and include subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas (AMLs), facial angiofibromas (FAs), and neuropsychiatric conditions such as autism spectrum disorder (ASD).

View Article and Find Full Text PDF

Aims: Previous studies suggest potential associations between epilepsy, anti-epileptic drugs (AEDs), and levels of vitamin D and vitamin D-binding protein (VDBP). This study aims to investigate the causal relationships among these variables using Mendelian Randomization (MR) methods.

Methods: Using summary data from genome-wide association studies on serum 25-hydroxyvitamin D [25(OH)D] levels (N = 417,580), VDBP concentrations (N = 65,589), and various types of epilepsy (Ncases = 27,559), MR analyses were conducted to determine bidirectional causal relationships among these variables.

View Article and Find Full Text PDF

Valproic acid (VPA) is a classic broad-spectrum antiepileptic drug, with significant pharmacokinetic variability. Genetic polymorphisms contribute to this variability, influencing both VPA trough serum concentration (VPA concentration) and VPA-induced liver injury. Our study aims to investigate the association between polymorphisms of uridine diphosphate glucuronyl transferase () , and VPA concentration and screen for potential genetic loci affecting VPA-induced liver injury.

View Article and Find Full Text PDF
Article Synopsis
  • Antiseizure medications, like valproic acid (VPA), show different results in patients due to genetic factors, though there's limited research specifically on VPA compared to other drugs.
  • This study aimed to analyze how genetic variations influence the effectiveness, side effects, and serum levels of VPA in patients with genetic generalized epilepsies (GGE).
  • The results revealed that certain genetic variants are linked to treatment failure, increased serum levels, weight gain, and hair loss among GGE patients using VPA, suggesting a need for personalized medication approaches.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!